You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Carbamazepine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for carbamazepine and what is the scope of patent protection?

Carbamazepine is the generic ingredient in eight branded drugs marketed by Apotex Inc, Nostrum Labs Inc, Taro, Teva Pharms, Takeda Pharms Usa, Validus Pharms, Lundbeck Pharms Llc, Chartwell Rx, Novitium Pharma, Novartis, Jubilant Cadista, Taro Pharm Inds, Torrent Pharms, Teva, Ajanta Pharma Ltd, Amneal Pharms, Anbison Lab, Cspc Ouyi, Riconpharma Llc, Sciecure Pharma Inc, Umedica, Unique Pharm, Zhejiang Jiuzhou, Zydus Pharms, Actavis Elizabeth, Bionpharma, Inwood Labs, Pliva, Rk Pharma, Unichem, Usl Pharma, and Warner Chilcott, and is included in forty-four NDAs. There are eight patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Carbamazepine has seventy-eight patent family members in twenty-one countries.

There are twenty-seven drug master file entries for carbamazepine. Forty-six suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for carbamazepine

See drug prices for carbamazepine

Drug Sales Revenue Trends for carbamazepine

See drug sales revenues for carbamazepine

Recent Clinical Trials for carbamazepine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aligos TherapeuticsPhase 1
Dr Cipto Mangunkusumo General HospitalPhase 4
Kathmandu UniversityPhase 4

See all carbamazepine clinical trials

Generic filers with tentative approvals for CARBAMAZEPINE
Applicant Application No. Strength Dosage Form
⤷  Try a Trial⤷  Try a Trial300MGCAPSULE, EXTENDED RELEASE; ORAL
⤷  Try a Trial⤷  Try a Trial200MGCAPSULE, EXTENDED RELEASE; ORAL
⤷  Try a Trial⤷  Try a Trial100MGCAPSULE, EXTENDED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for carbamazepine
Anatomical Therapeutic Chemical (ATC) Classes for carbamazepine
Paragraph IV (Patent) Challenges for CARBAMAZEPINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EQUETRO Extended-release Capsules carbamazepine 100 mg 021710 1 2014-05-23
EQUETRO Extended-release Capsules carbamazepine 200 mg and 300 mg 021710 1 2007-08-21
CARBATROL Extended-release Capsules carbamazepine 100 mg and 200 mg 020712 1 2006-02-02
TEGRETOL-XR Extended-release Tablets carbamazepine 100 mg 020234 1 2005-12-30

US Patents and Regulatory Information for carbamazepine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro CARBAMAZEPINE carbamazepine SUSPENSION;ORAL 075875-001 Dec 21, 2000 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms CARBAMAZEPINE carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 078592-001 Sep 20, 2012 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Torrent Pharms CARBAMAZEPINE carbamazepine TABLET, CHEWABLE;ORAL 075712-001 Jul 5, 2001 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zhejiang Jiuzhou CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 215591-003 Mar 31, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Jubilant Cadista CARBAMAZEPINE carbamazepine TABLET, CHEWABLE;ORAL 071940-001 Feb 1, 1988 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa CARBATROL carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 020712-001 Sep 30, 1997 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for carbamazepine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TEGRETOL carbamazepine TABLET;ORAL 016608-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa CARBATROL carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 020712-002 Sep 30, 1997 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa CARBATROL carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 020712-001 Sep 30, 1997 ⤷  Try a Trial ⤷  Try a Trial
Novartis TEGRETOL carbamazepine SUSPENSION;ORAL 018927-001 Dec 18, 1987 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa CARBATROL carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 020712-001 Sep 30, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for carbamazepine

Country Patent Number Title Estimated Expiration
South Africa 200803332 NOVEL PARENTERAL CARBAMAZEPINE FORMULATION ⤷  Try a Trial
Russian Federation 2012112839 НОВАЯ ПАРЕНТЕРАЛЬНАЯ КОМПОЗИЦИЯ КАРБАМАЗЕПИНА ⤷  Try a Trial
Japan 6039721 ⤷  Try a Trial
Japan 5794966 ⤷  Try a Trial
Mexico 2008004287 FORMULACION DE CARBAMAZEPINA PARENTERAL NOVEDOSA. (NOVEL PARENTERAL CARBAMAZEPINE FORMULATION.) ⤷  Try a Trial
Russian Federation 2008117161 НОВАЯ ПАРЕНТЕРАЛЬНАЯ КОМПОЗИЦИЯ КАРБАМАЗЕПИНА ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.